Krasimira Rozenova, MD, PhD
she/her/hers
Assistant ProfessorAbout
Research
Publications
2026
Leukemic Non-Nodal Mantle Cell Lymphoma Presenting with Traumatic Splenic Rupture
Haque M, Amraei R, Rozenova K. Leukemic Non-Nodal Mantle Cell Lymphoma Presenting with Traumatic Splenic Rupture. Hematology Reports 2026, 18: 32. PMID: 42200827, PMCID: PMC13214678, DOI: 10.3390/hematolrep18030032.Peer-Reviewed Original ResearchMantle cell lymphomaOne-month historyCell lymphomaFluorescence in situ hybridizationClinical findingsLeukemic non-nodal mantle cell lymphomaNon-nodal mantle cell lymphomaSubtypes of mantle cell lymphomaConclusions:Peripheral blood flow cytometryFlow cytometryAdverse genetic alterationsAtypical lymphoid cellsIndolent clinical courseBlood flow cytometryPeripheral blood findingsWhite blood cell countKi-67 indexHistory of anemiaB cell populationsLow disease burdenTraumatic splenic ruptureComplete blood countBlood cell countTotal white blood cell countGene expression and immunohistochemical phenotypes of high-grade epithelioid mesothelioma
Gagnon M, Rozenova K, Lu C, Sosa C, Pitel B, Petersen M, Clausen S, Roden A, Halling K, Lo Y. Gene expression and immunohistochemical phenotypes of high-grade epithelioid mesothelioma. Human Pathology 2026, 173: 106118. PMID: 41967647, DOI: 10.1016/j.humpath.2026.106118.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorEnhancer of Zeste Homolog 2 ProteinEpithelioid CellsFemaleGene Expression ProfilingHumansImmunohistochemistryLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMiddle AgedNeoplasm GradingPhenotypePleural NeoplasmsTumor Suppressor ProteinsUbiquitin ThiolesteraseConceptsEpithelioid mesotheliomaPD-L1Histological gradeBiphasic mesotheliomaImmunohistochemical phenotypeClinical managementHigh-gradeLow PD-L1 expressionManagement of pleural mesotheliomaExpression of PD-L1Sarcomatoid/desmoplastic mesotheliomasPD-L1 IHCPD-L1 expressionRNA expressionNon-statistically significant trendPanCancer Pathways PanelPredictive of survivalHeterogeneous expression profilesBAP1 lossWHO classificationExpression profilesPleural mesotheliomaIHC profileFFPE slidesMesothelioma biopsies
2025
A 20‐color 21‐antigen flow cytometric assay for disease monitoring of T‐cell lymphoblastic leukemia
Gao Q, Zhang J, Rozenova K, Sun X, Burke A, Miu O, Nguyen N, Zhang S, Roshal M. A 20‐color 21‐antigen flow cytometric assay for disease monitoring of T‐cell lymphoblastic leukemia. Cytometry Part B Clinical Cytometry 2025, 108: 299-311. PMID: 40605707, DOI: 10.1002/cyto.b.22242.Peer-Reviewed Original ResearchConceptsT-lineage acute lymphoblastic leukemiaThymic precursorsAggressive neoplasmLymphoblastic leukemiaImmature T-cell phenotypeFlow cytometryT lymphoblastsEarly T-cell precursorT-cell lymphoblastic leukemiaEvaluation of mediastinal diseaseMinimal/measurable residual diseaseT-cell phenotypeTherapy decision-makingFollow-up measurementsImmature T cellsT cell precursorsAcute lymphoblastic leukemiaDisease monitoringResidual diseaseMediastinal diseaseT cellsFollow-upAntigenic changesNumerous antigensTissue samplesAtypical squamous proliferation diagnosed on biopsy has a high risk of representing squamous cell carcinoma
Rozenova K, Reed K, Guo R. Atypical squamous proliferation diagnosed on biopsy has a high risk of representing squamous cell carcinoma. JAAD International 2025, 20: 1-3. PMID: 40213529, PMCID: PMC11979433, DOI: 10.1016/j.jdin.2025.01.008.Peer-Reviewed Original ResearchGestational trophoblastic disease: STR genotyping for precision diagnosis
Rozenova K, Buza N, Hui P. Gestational trophoblastic disease: STR genotyping for precision diagnosis. Expert Review Of Molecular Diagnostics 2025, 25: 1-19. PMID: 39801212, DOI: 10.1080/14737159.2025.2453506.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsShort tandem repeatsGestational trophoblastic diseaseShort tandem repeat genotypingDiagnosis of gestational trophoblastic diseaseGestational trophoblastic tumorsHydatidiform MoleSTR genotypingTrophoblastic tumorDifferential diagnosis of gestational trophoblastic diseaseRepetitive DNA sequencesManagement of gestational trophoblastic diseaseSubclassification of hydatidiform molesGestational trophoblastic neoplasmsPrognostication of patientsPaternity testingNon-neoplastic natureHuman genomeTandem repeatsDNA sequencesForensic identityTrophoblastic diseaseTrophoblastic neoplasmsGynecologic conditionsDiagnostic workupClinical outcomes
2023
Kappa Free Light Chain Drift Prompts the Need for a New Upper Limit of Normal Free Light Chain Ratio to Avoid an Epidemic of Kappa Light Chain Monoclonal Gammopathy of Undermined Significance
Rozenova K, Willrich M, Snyder M, Dasari S, Kourelis T, Rajkumar S, Kumar S, Dispenzieri A, Murray D. Kappa Free Light Chain Drift Prompts the Need for a New Upper Limit of Normal Free Light Chain Ratio to Avoid an Epidemic of Kappa Light Chain Monoclonal Gammopathy of Undermined Significance. The Journal Of Applied Laboratory Medicine 2023, 8: 742-750. PMID: 37232112, DOI: 10.1093/jalm/jfad027.Peer-Reviewed Original ResearchConceptsPlasma cell disorderFree light chainsSerum protein electrophoresisMonoclonal proteinFree light chain ratioFree light chain assayKappa free light chainsLight chain ratioDetection of monoclonal proteinsGroup of patientsProtein electrophoresisMASS-FIXMultiple laboratory testsFLC ratioCell disordersRetrospective studyImmunofixation electrophoresisPatientsChain ratioRFLCSerumLight chainMass spectrometryLaboratory testsElectrophoresisPrimary thymic marginal zone lymphoma with amyloidosis
Rozenova K, Xiao W. Primary thymic marginal zone lymphoma with amyloidosis. Blood 2023, 141: 1494-1494. PMID: 36951878, PMCID: PMC10082368, DOI: 10.1182/blood.2022019001.Peer-Reviewed Original ResearchDedifferentiation of B-lymphoblastic leukemia/lymphoma with t(9;22) BCR::ABL1 to an undifferentiated neoplasm with strong keratin expression in a patient receiving blinatumomab
Rozenova K, Roden A, Hartley C, Peterson J, Otteson G, Al-Kali A, Bayne H, Shah M, Patnaik M, King R, Larson D. Dedifferentiation of B-lymphoblastic leukemia/lymphoma with t(9;22) BCR::ABL1 to an undifferentiated neoplasm with strong keratin expression in a patient receiving blinatumomab. Human Pathology Reports 2023, 31: 300688. DOI: 10.1016/j.hpr.2022.300688.Peer-Reviewed Original ResearchAberrant keratin expressionB-ALLUndifferentiated neoplasmsKeratin expressionCases of lymphoblastic leukaemiaBone marrow relapseB-lymphoblastic leukemia/lymphomaMulti-agent therapyChest wall massInitiation of treatmentExpression of keratinMarrow relapseMyeloid antigensEarly relapseAcute leukemiaLymphoblastic leukemiaT cellsLineage switchKeratin-positiveBlinatumomabLineage-specific differentiationWall massNeoplasmsDedifferentiated neoplasmsBCR::ABL1Dedifferentiation of B-lymphoblastic leukemia/lymphoma with t(9;22) BCR::ABL1 to an undifferentiated neoplasm with strong keratin expression in a patient receiving blinatumomab
Rozenova KA, et al. Dedifferentiation of B-lymphoblastic leukemia/lymphoma with t(9;22) BCR::ABL1 to an undifferentiated neoplasm with strong keratin expression in a patient receiving blinatumomab, Human Pathology Reports, Volume 31, 2023, 300688, ISSN2772-736XPeer-Reviewed Case Reports and Technical Notes
2022
Utilization of skin biopsy for diagnosis in a case of Lafora disease
Rozenova K, Lehman J, Grande J, Fine A, Wieland C. Utilization of skin biopsy for diagnosis in a case of Lafora disease. Journal Of Cutaneous Pathology 2022, 49: 885-888. PMID: 35708461, DOI: 10.1111/cup.14275.Peer-Reviewed Original ResearchConceptsSkin biopsiesProgressive myoclonic seizuresProgressive neurological symptomsNHLRC1 geneNeurological symptomsMyoclonic seizuresHistopathological examinationHomozygous mutationLafora diseaseBiopsyCases of Lafora diseaseElectron microscopic examinationSweat glandsPathological mutationsDiagnosisNeurological disordersDiseaseMicroscopic examinationMutationsSkinExaminationTissueGenesNHLRC1
Academic Achievements & Community Involvement
News
News
Get In Touch
Contacts
Locations
BML35
Academic Office
Brady Memorial Laboratory
310 Cedar St
New Haven, CT 06510